Free Trial

OrthoPediatrics (KIDS) Competitors

OrthoPediatrics logo
$17.82 0.00 (0.00%)
Closing price 06/12/2026 04:00 PM Eastern
Extended Trading
$17.84 +0.02 (+0.11%)
As of 06/12/2026 05:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

KIDS vs. PLSE, PRCT, CDRE, TNDM, and BLFS

Should you buy OrthoPediatrics stock or one of its competitors? MarketBeat compares OrthoPediatrics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with OrthoPediatrics include Pulse Biosciences (PLSE), PROCEPT BioRobotics (PRCT), Cadre (CDRE), Tandem Diabetes Care (TNDM), and BioLife Solutions (BLFS). These companies are all part of the "medical equipment" industry.

How does OrthoPediatrics compare to Pulse Biosciences?

OrthoPediatrics (NASDAQ:KIDS) and Pulse Biosciences (NASDAQ:PLSE) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership and earnings.

In the previous week, Pulse Biosciences had 3 more articles in the media than OrthoPediatrics. MarketBeat recorded 6 mentions for Pulse Biosciences and 3 mentions for OrthoPediatrics. OrthoPediatrics' average media sentiment score of 0.63 beat Pulse Biosciences' score of 0.31 indicating that OrthoPediatrics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
OrthoPediatrics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Pulse Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

69.1% of OrthoPediatrics shares are owned by institutional investors. Comparatively, 77.0% of Pulse Biosciences shares are owned by institutional investors. 31.8% of OrthoPediatrics shares are owned by company insiders. Comparatively, 74.0% of Pulse Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

OrthoPediatrics currently has a consensus price target of $24.44, suggesting a potential upside of 37.17%. Pulse Biosciences has a consensus price target of $30.67, suggesting a potential upside of 25.84%. Given OrthoPediatrics' stronger consensus rating and higher probable upside, equities research analysts clearly believe OrthoPediatrics is more favorable than Pulse Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
OrthoPediatrics
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.82
Pulse Biosciences
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

Pulse Biosciences has a net margin of 0.00% compared to OrthoPediatrics' net margin of -16.31%. OrthoPediatrics' return on equity of -7.01% beat Pulse Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
OrthoPediatrics-16.31% -7.01% -4.86%
Pulse Biosciences N/A -86.67%-73.61%

OrthoPediatrics has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than OrthoPediatrics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OrthoPediatrics$236.35M1.94-$39.65M-$1.68N/A
Pulse Biosciences$350K4,818.99-$72.78M-$1.10N/A

OrthoPediatrics has a beta of 1.03, indicating that its stock price is 3% more volatile than the broader market. Comparatively, Pulse Biosciences has a beta of 1.65, indicating that its stock price is 65% more volatile than the broader market.

Summary

OrthoPediatrics beats Pulse Biosciences on 10 of the 17 factors compared between the two stocks.

How does OrthoPediatrics compare to PROCEPT BioRobotics?

OrthoPediatrics (NASDAQ:KIDS) and PROCEPT BioRobotics (NASDAQ:PRCT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

69.1% of OrthoPediatrics shares are owned by institutional investors. Comparatively, 89.5% of PROCEPT BioRobotics shares are owned by institutional investors. 31.8% of OrthoPediatrics shares are owned by company insiders. Comparatively, 17.4% of PROCEPT BioRobotics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

OrthoPediatrics has higher earnings, but lower revenue than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than OrthoPediatrics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OrthoPediatrics$236.35M1.94-$39.65M-$1.68N/A
PROCEPT BioRobotics$308.05M4.75-$95.57M-$1.82N/A

OrthoPediatrics has a net margin of -16.31% compared to PROCEPT BioRobotics' net margin of -31.82%. OrthoPediatrics' return on equity of -7.01% beat PROCEPT BioRobotics' return on equity.

Company Net Margins Return on Equity Return on Assets
OrthoPediatrics-16.31% -7.01% -4.86%
PROCEPT BioRobotics -31.82%-27.70%-20.29%

OrthoPediatrics has a beta of 1.03, suggesting that its stock price is 3% more volatile than the broader market. Comparatively, PROCEPT BioRobotics has a beta of 0.85, suggesting that its stock price is 15% less volatile than the broader market.

In the previous week, PROCEPT BioRobotics had 10 more articles in the media than OrthoPediatrics. MarketBeat recorded 13 mentions for PROCEPT BioRobotics and 3 mentions for OrthoPediatrics. OrthoPediatrics' average media sentiment score of 0.63 beat PROCEPT BioRobotics' score of 0.36 indicating that OrthoPediatrics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
OrthoPediatrics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
PROCEPT BioRobotics
4 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

OrthoPediatrics presently has a consensus target price of $24.44, suggesting a potential upside of 37.17%. PROCEPT BioRobotics has a consensus target price of $41.36, suggesting a potential upside of 60.95%. Given PROCEPT BioRobotics' higher probable upside, analysts plainly believe PROCEPT BioRobotics is more favorable than OrthoPediatrics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
OrthoPediatrics
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.82
PROCEPT BioRobotics
2 Sell rating(s)
5 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.36

Summary

OrthoPediatrics beats PROCEPT BioRobotics on 12 of the 17 factors compared between the two stocks.

How does OrthoPediatrics compare to Cadre?

OrthoPediatrics (NASDAQ:KIDS) and Cadre (NYSE:CDRE) are both small-cap medical equipment companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, media sentiment, dividends, risk and analyst recommendations.

Cadre has higher revenue and earnings than OrthoPediatrics. OrthoPediatrics is trading at a lower price-to-earnings ratio than Cadre, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OrthoPediatrics$236.35M1.94-$39.65M-$1.68N/A
Cadre$610.31M2.14$44.14M$0.8934.31

In the previous week, OrthoPediatrics had 1 more articles in the media than Cadre. MarketBeat recorded 3 mentions for OrthoPediatrics and 2 mentions for Cadre. Cadre's average media sentiment score of 1.18 beat OrthoPediatrics' score of 0.63 indicating that Cadre is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
OrthoPediatrics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Cadre
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

OrthoPediatrics has a beta of 1.03, indicating that its share price is 3% more volatile than the broader market. Comparatively, Cadre has a beta of 1.32, indicating that its share price is 32% more volatile than the broader market.

69.1% of OrthoPediatrics shares are held by institutional investors. Comparatively, 44.0% of Cadre shares are held by institutional investors. 31.8% of OrthoPediatrics shares are held by company insiders. Comparatively, 30.1% of Cadre shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Cadre has a net margin of 5.80% compared to OrthoPediatrics' net margin of -16.31%. Cadre's return on equity of 12.39% beat OrthoPediatrics' return on equity.

Company Net Margins Return on Equity Return on Assets
OrthoPediatrics-16.31% -7.01% -4.86%
Cadre 5.80%12.39%5.08%

OrthoPediatrics presently has a consensus price target of $24.44, suggesting a potential upside of 37.17%. Cadre has a consensus price target of $39.75, suggesting a potential upside of 30.16%. Given OrthoPediatrics' stronger consensus rating and higher possible upside, analysts plainly believe OrthoPediatrics is more favorable than Cadre.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
OrthoPediatrics
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.82
Cadre
1 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.57

Summary

Cadre beats OrthoPediatrics on 10 of the 16 factors compared between the two stocks.

How does OrthoPediatrics compare to Tandem Diabetes Care?

Tandem Diabetes Care (NASDAQ:TNDM) and OrthoPediatrics (NASDAQ:KIDS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, media sentiment, risk, profitability, analyst recommendations and dividends.

Tandem Diabetes Care presently has a consensus target price of $29.84, suggesting a potential upside of 79.77%. OrthoPediatrics has a consensus target price of $24.44, suggesting a potential upside of 37.17%. Given Tandem Diabetes Care's higher possible upside, research analysts clearly believe Tandem Diabetes Care is more favorable than OrthoPediatrics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tandem Diabetes Care
1 Sell rating(s)
10 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.48
OrthoPediatrics
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.82

Tandem Diabetes Care has a beta of 1.58, indicating that its stock price is 58% more volatile than the broader market. Comparatively, OrthoPediatrics has a beta of 1.03, indicating that its stock price is 3% more volatile than the broader market.

Tandem Diabetes Care has a net margin of -9.20% compared to OrthoPediatrics' net margin of -16.31%. OrthoPediatrics' return on equity of -7.01% beat Tandem Diabetes Care's return on equity.

Company Net Margins Return on Equity Return on Assets
Tandem Diabetes Care-9.20% -53.88% -7.88%
OrthoPediatrics -16.31%-7.01%-4.86%

OrthoPediatrics has lower revenue, but higher earnings than Tandem Diabetes Care. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than OrthoPediatrics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tandem Diabetes Care$1.03B1.11-$204.71M-$1.40N/A
OrthoPediatrics$236.35M1.94-$39.65M-$1.68N/A

In the previous week, Tandem Diabetes Care had 2 more articles in the media than OrthoPediatrics. MarketBeat recorded 5 mentions for Tandem Diabetes Care and 3 mentions for OrthoPediatrics. Tandem Diabetes Care's average media sentiment score of 0.80 beat OrthoPediatrics' score of 0.63 indicating that Tandem Diabetes Care is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Tandem Diabetes Care
3 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
OrthoPediatrics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

69.1% of OrthoPediatrics shares are owned by institutional investors. 2.1% of Tandem Diabetes Care shares are owned by company insiders. Comparatively, 31.8% of OrthoPediatrics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Tandem Diabetes Care and OrthoPediatrics tied by winning 8 of the 16 factors compared between the two stocks.

How does OrthoPediatrics compare to BioLife Solutions?

OrthoPediatrics (NASDAQ:KIDS) and BioLife Solutions (NASDAQ:BLFS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, dividends, analyst recommendations, institutional ownership, valuation and profitability.

69.1% of OrthoPediatrics shares are held by institutional investors. Comparatively, 93.2% of BioLife Solutions shares are held by institutional investors. 31.8% of OrthoPediatrics shares are held by company insiders. Comparatively, 2.2% of BioLife Solutions shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

BioLife Solutions has lower revenue, but higher earnings than OrthoPediatrics. BioLife Solutions is trading at a lower price-to-earnings ratio than OrthoPediatrics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OrthoPediatrics$236.35M1.94-$39.65M-$1.68N/A
BioLife Solutions$96.21M13.25-$4.59M-$0.08N/A

BioLife Solutions has a net margin of -2.80% compared to OrthoPediatrics' net margin of -16.31%. BioLife Solutions' return on equity of 1.81% beat OrthoPediatrics' return on equity.

Company Net Margins Return on Equity Return on Assets
OrthoPediatrics-16.31% -7.01% -4.86%
BioLife Solutions -2.80%1.81%1.65%

In the previous week, OrthoPediatrics had 2 more articles in the media than BioLife Solutions. MarketBeat recorded 3 mentions for OrthoPediatrics and 1 mentions for BioLife Solutions. BioLife Solutions' average media sentiment score of 1.88 beat OrthoPediatrics' score of 0.63 indicating that BioLife Solutions is being referred to more favorably in the news media.

Company Overall Sentiment
OrthoPediatrics Positive
BioLife Solutions Very Positive

OrthoPediatrics presently has a consensus price target of $24.44, indicating a potential upside of 37.17%. BioLife Solutions has a consensus price target of $32.00, indicating a potential upside of 22.61%. Given OrthoPediatrics' stronger consensus rating and higher possible upside, analysts clearly believe OrthoPediatrics is more favorable than BioLife Solutions.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
OrthoPediatrics
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.82
BioLife Solutions
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

OrthoPediatrics has a beta of 1.03, suggesting that its share price is 3% more volatile than the broader market. Comparatively, BioLife Solutions has a beta of 2, suggesting that its share price is 100% more volatile than the broader market.

Summary

BioLife Solutions beats OrthoPediatrics on 9 of the 17 factors compared between the two stocks.

Get OrthoPediatrics News Delivered to You Automatically

Sign up to receive the latest news and ratings for KIDS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KIDS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KIDS vs. The Competition

MetricOrthoPediatricsMED INSTRUMENTS IndustryMedical SectorNASDAQ Exchange
Market Cap$457.62M$7.04B$6.52B$12.05B
Dividend YieldN/A1.21%2.67%5.66%
P/E Ratio-10.6147.8824.0024.42
Price / Sales1.9470.95516.42110.81
Price / Cash107.1725.5927.4837.92
Price / Book1.296.8410.746.82
Net Income-$39.65M$159.20M$3.57B$337.56M
7 Day Performance-2.25%-0.93%0.58%1.16%
1 Month Performance0.56%5.15%1.48%3.16%
1 Year Performance-15.78%1.23%25.41%30.60%

OrthoPediatrics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KIDS
OrthoPediatrics
3.035 of 5 stars
$17.82
flat
$24.44
+37.2%
-15.8%$457.62M$236.35MN/A200
PLSE
Pulse Biosciences
3.408 of 5 stars
$24.28
-1.6%
$30.00
+23.6%
+54.5%$1.71B$350KN/A140
PRCT
PROCEPT BioRobotics
2.9918 of 5 stars
$26.76
-3.9%
$41.45
+54.9%
-57.6%$1.59B$308.05MN/A430
CDRE
Cadre
4.5602 of 5 stars
$30.23
-1.3%
$39.75
+31.5%
-11.4%$1.31B$610.31M33.972,533
TNDM
Tandem Diabetes Care
2.4843 of 5 stars
$18.60
-2.7%
$29.84
+60.4%
-20.0%$1.31B$1.01BN/A2,500

Related Companies and Tools


This page (NASDAQ:KIDS) was last updated on 6/15/2026 by MarketBeat.com Staff.
From Our Partners